MA24691A1 - Formulation a liberation prolongee - Google Patents

Formulation a liberation prolongee

Info

Publication number
MA24691A1
MA24691A1 MA25330A MA25330A MA24691A1 MA 24691 A1 MA24691 A1 MA 24691A1 MA 25330 A MA25330 A MA 25330A MA 25330 A MA25330 A MA 25330A MA 24691 A1 MA24691 A1 MA 24691A1
Authority
MA
Morocco
Prior art keywords
provides
extended release
release formulation
venlafaxine
extended
Prior art date
Application number
MA25330A
Other languages
English (en)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA24691(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Publication of MA24691A1 publication Critical patent/MA24691A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

CETTE INVENTION CONCERNE UNE FORMUTALION DE DOSAGE à LIBÉRATION PROLONGÉE DE 24 HEURES ET SA FORME DOSÉE UNITAIRE DE CHLORHYDRATE DE VENLAFAXINE, UN ANTIDÉPRESSEUR, QUI FOURNIT UN MEILLEUR CONTRôLE DES TAUX PLASMATIQUES SANGUINS QUE LES FRMULATIONS CLASSIQUES DE COMPRIMÉS QUI DOIVENT eTRE ADMINISTRÉES DEUX OU PLUSIEURS FOIS PAR JOUR ET FOURNIT EN OUTRE UNE INCIDENCE PLUS FAIBLE DE NAUSÉE ET DE VOMISSEMENT QUE LES COMPRIMÉS CLASSIQUES. DANS SON PREINCIPAL ASPECT, L'INVENTION FOURNIT UN NOYAU AMÉLIORÉ DES SPHÉROiDRES à LIBÉRATION PROLONGÉE CONSTITUÉ DE CHLORGYDRATE DE VENLAFAXINE ET DE CELLULOSES MICROCRITALLINE, CECI SANS L'ADDITION D'HYDROXYPROPYL-MÉTHYCELLULOSE.
MA25330A 1997-11-05 1998-11-02 Formulation a liberation prolongee MA24691A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05

Publications (1)

Publication Number Publication Date
MA24691A1 true MA24691A1 (fr) 1999-07-01

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25330A MA24691A1 (fr) 1997-11-05 1998-11-02 Formulation a liberation prolongee

Country Status (38)

Country Link
EP (1) EP1028718B1 (fr)
JP (1) JP2001521892A (fr)
KR (1) KR20010031797A (fr)
CN (1) CN1278165A (fr)
AR (1) AR014012A1 (fr)
AT (1) ATE237320T1 (fr)
AU (1) AU747978B2 (fr)
BG (1) BG104397A (fr)
BR (1) BR9813179A (fr)
CA (1) CA2305242A1 (fr)
CL (1) CL2004001705A1 (fr)
CO (1) CO5011060A1 (fr)
CZ (1) CZ20001659A3 (fr)
DE (1) DE69813602T2 (fr)
DK (1) DK1028718T3 (fr)
EA (1) EA200000487A1 (fr)
EE (1) EE04577B1 (fr)
ES (1) ES2196620T3 (fr)
GE (1) GEP20043198B (fr)
HR (1) HRP20000213B1 (fr)
HU (1) HU225238B1 (fr)
ID (1) ID26317A (fr)
IL (1) IL135457A0 (fr)
MA (1) MA24691A1 (fr)
NO (1) NO20002126L (fr)
NZ (1) NZ504460A (fr)
PA (1) PA8462501A1 (fr)
PE (1) PE128699A1 (fr)
PL (1) PL341141A1 (fr)
PT (1) PT1028718E (fr)
SK (1) SK6472000A3 (fr)
SV (1) SV1998000131A (fr)
TR (1) TR200001232T2 (fr)
TW (1) TW555568B (fr)
UA (1) UA77145C2 (fr)
UY (2) UY25234A1 (fr)
WO (1) WO1999022724A2 (fr)
ZA (1) ZA9810081B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
ES2290027T3 (es) * 1999-05-20 2008-02-16 Elan Corporation, Plc Formulaciones multiparticuladas y de liberacion controlada de inhibidores selectivos de la recaptacion de serotonina.
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US7030164B2 (en) * 2001-12-05 2006-04-18 Wyeth Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
AU2002247945A1 (en) * 2001-12-13 2003-06-23 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
EP1474123A1 (fr) * 2002-01-03 2004-11-10 LEK Pharmaceuticals D.D. Formulation pharmaceutique a liberation controlee contenant de la venlafaxine
WO2003082804A1 (fr) 2002-03-28 2003-10-09 Synthon B.V. Besylate de venlafaxine
AR039162A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Formulaciones de venlafaxina de liberacion extendida
AU2003226751A1 (en) 2002-03-28 2003-10-13 Synthon B.V. Low water-soluble venlafaxine salts
AU2003226748A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Compositions of venlafaxine base
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (fr) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Preparations a liberation modifiee contenant des inhibiteurs selectifs de la recapture de la serotonine
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
DK1502587T3 (da) * 2003-07-30 2007-01-02 Pharmathen Sa Formulering med vedvarende frigivelse af venlafaxinhydrochlorid
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
WO2005074895A1 (fr) * 2004-02-04 2005-08-18 Alembic Limited Micro-comprimes revetus a liberation prolongee de chlorhydrate de venlafaxine
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
CA2648278C (fr) * 2006-04-03 2019-05-28 Isa Odidi Composition d'administration de medicament
WO2007129329A2 (fr) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Préparation pharmaceutique à libération prolongée comprenant du chlorhydrate de venlafaxine
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
PT1028718E (pt) 2003-07-31
TW555568B (en) 2003-10-01
EP1028718A2 (fr) 2000-08-23
GEP20043198B (en) 2004-03-25
WO1999022724A3 (fr) 1999-07-22
WO1999022724A2 (fr) 1999-05-14
BR9813179A (pt) 2000-08-22
JP2001521892A (ja) 2001-11-13
PA8462501A1 (es) 2000-05-24
SK6472000A3 (en) 2000-11-07
CL2004001705A1 (es) 2005-06-03
NZ504460A (en) 2003-01-31
EE200000212A (et) 2001-04-16
AR014012A1 (es) 2001-01-31
EA200000487A1 (ru) 2000-10-30
HK1029056A1 (en) 2001-03-23
CA2305242A1 (fr) 1999-05-14
DK1028718T3 (da) 2003-07-28
ES2196620T3 (es) 2003-12-16
TR200001232T2 (tr) 2000-12-21
PE128699A1 (es) 2000-01-06
AU747978B2 (en) 2002-05-30
BG104397A (en) 2001-02-28
ATE237320T1 (de) 2003-05-15
UY25234A1 (es) 2000-12-29
CO5011060A1 (es) 2001-02-28
CZ20001659A3 (cs) 2001-10-17
HUP0004287A3 (en) 2002-05-28
DE69813602T2 (de) 2003-11-06
DE69813602D1 (de) 2003-05-22
NO20002126L (no) 2000-05-04
ZA9810081B (en) 2000-05-04
HUP0004287A2 (hu) 2002-04-29
NO20002126D0 (no) 2000-04-26
HRP20000213A2 (en) 2000-12-31
SV1998000131A (es) 1999-11-18
PL341141A1 (en) 2001-03-26
IL135457A0 (en) 2001-05-20
UA77145C2 (en) 2006-11-15
HRP20000213B1 (en) 2004-04-30
AU1300399A (en) 1999-05-24
HU225238B1 (en) 2006-08-28
EE04577B1 (et) 2006-02-15
UY25692A1 (es) 2000-03-31
ID26317A (id) 2000-12-14
CN1278165A (zh) 2000-12-27
KR20010031797A (ko) 2001-04-16
EP1028718B1 (fr) 2003-04-16

Similar Documents

Publication Publication Date Title
MA24691A1 (fr) Formulation a liberation prolongee
PT881901E (pt) Novas associacoes de principios activos contendo clopidogrel e um agente anti-trombotico
MD1920F2 (ro) Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
MY129234A (en) Oral pharmaceutical forms of administration with a delayed action with tramadol.
PT797991E (pt) Formulacao com libertacao prolongada contendo venlafaxina
TR199802423T2 (xx) Konsantre antikor terkibi.
EA200000246A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
CA2601289A1 (fr) Formulations d'oxycodone a administration quotidienne unique
RU2008143545A (ru) Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2
DE50206576D1 (de) Medizinisches implantat für den menschlichen oder tierischen körper
AR064896A2 (es) Composicion farmaceutica no higroscopica
CA2269745A1 (fr) Traitement ameliore contre la migraine
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
RU99120072A (ru) Способ и композиция для профилактики и задержки начала болезни Альцгеймера
UA41392C2 (uk) Швидкорозчинна таблетка трамадолу або солі трамадолу
EA200000245A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
BR0203902A (pt) Composições de compostos bioquìmicos envolvidos no metabolismo bioenergético das células e método de uso da mesma
CA2325739A1 (fr) Combinaison destinee au traitement de la dependance a l'alcool et aux drogues contenant un antagoniste d'opioides et un modulateur du complexe du recepteur nmda
Levin et al. Recurrent Primary Brain Tumors 1, 2
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
CA2203310A1 (fr) Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
ITRM970254A0 (it) Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía